Multi-center evaluation of the Research Use Only NeuMoDx monkeypox virus (MPXV) fully automated real-time PCR assay
Journal of Clinical Microbiology · 2024
DOI: 10.1128/jcm.00028-24 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, 2024. Verfasst von Heba H Mostafa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Microbiology, Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Sensitivity and Specificity, Monkeypox virus, Real-Time Polymerase Chain Reaction, Mpox, Monkeypox. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: QIAGEN (QIAGEN LLC - USA).
Abstract (Originalsprache)
The mpox outbreak, caused by monkeypox virus (MPXV), accelerated the development of molecular diagnostics. In this study, we detail the evaluation of the Research Use Only (RUO) NeuMoDx MPXV assay by multiple European and US sites. The assay was designed and developed by Qiagen for the NeuMoDx Molecular Systems. Primers and probes were tested for specificity and inclusivity in silico . The analytical sensitivity of the assay was determined by testing dilutions of synthetic and genomic MPXV DNA. A total of 296 clinical samples were tested by three sites; the Johns Hopkins University (US), UZ Gent (Belgium, Europe), and Hospital Universitario San Cecilio (Spain, Europe). The analytical sensitivity of the assay was 50 copies/mL for both clades I and II. The assay showed 100% in silico identity for 80 clade I and 99.98% in silico identity for 5,162 clade II genomes. Clade II primers and probes showed 100% in silico specificity; however, identity of at least one of the two sets of clade I primers and probes with variola, cowpox, camelpox, and vaccinia viruses was noticed. The clinical validation showed sensitivity of 99.21% [95% confidence interval (CI): 95.66–99.98%] and specificity of 96.64% (95% CI: 91.62–99.08%) for lesion swab samples. The NeuMoDx MPXV Test shows acceptable analytical and clinical performance. The assay improves the laboratory’s workflow as it consolidates nucleic acid extraction, PCR, data analysis, and interpretation and can be interfaced. The Test Strip can differentiate clades I and II, which has important laboratory safety implications. IMPORTANCE In this manuscript, we provide detailed in silico analysis and clinical evaluation of the assay using a large cohort of clinical samples across three academic centers in Europe and the United States. Because the assay differentiates MPXV clades I and II, this manuscript is timely due to the current need to rule out the regulated clade I by diagnostic clinical laboratories. In December 2023, and due to first report of cases of sexually transmitted clade I infections in the Democratic Republic of the Congo, when generic assays that do not differentiate the clades are used, samples are considered regulated. The assay meets the need of full automation and has a marked positive impact on the laboratory workflow.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Microbiology, Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- QIAGEN GmbH, Hilden, Germany.
- NeuMoDx Molecular Inc, a QIAGEN company, Ann Arbor, Michigan, USA.
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Universitair Ziekenhuis Gent, Gent, Belgium.
- Laboratory of Clinical and Epidemiological, Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
ORCID-Profile: Heba H Mostafa, Andrew Pekosz, Elizaveta Padalko, Federico Garcia
Förderung
- QIAGEN (QIAGEN LLC - USA)
Zitieren
APA
Mostafa, H. H., Wall, G., Su, S. C., Hysa, G., Gong, L., Dadjeu, U. C., Cheung, H., Pekosz, A., De Smet, D., Sklenovská, N., Laenen, L., Viñuela, L., de Salazar, A., Fuentes, A., Padalko, E., & Garcia, F. (2024). Multi-center evaluation of the Research Use Only NeuMoDx monkeypox virus (MPXV) fully automated real-time PCR assay. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00028-24
Vancouver
Mostafa HH, Wall G, Su SC, Hysa G, Gong L, Dadjeu UC, et al. Multi-center evaluation of the Research Use Only NeuMoDx monkeypox virus (MPXV) fully automated real-time PCR assay. Journal of Clinical Microbiology. 2024. doi:10.1128/jcm.00028-24
BibTeX
@article{Mostafa2024,
author = {Mostafa, Heba H and Wall, Gavin and Su, Szu-Chi and Hysa, Gerta and Gong, Lijie and Dadjeu, Urbain Charly and Cheung, Helen and Pekosz, Andrew and De Smet, Delphine and Sklenovská, Nikola and Laenen, Lies and Viñuela, Laura and de Salazar, Adolfo and Fuentes, Ana and Padalko, Elizaveta and Garcia, Federico},
title = {Multi-center evaluation of the Research Use Only NeuMoDx monkeypox virus (MPXV) fully automated real-time PCR assay},
journal = {Journal of Clinical Microbiology},
year = {2024},
doi = {10.1128/jcm.00028-24}
}
EUVIMED